title: [Study on the susceptibility of the cervical carcinoma cells to CTL lysis under the stimulation of rSIFN-co and its mechanism].
abstract: OBJECTIVE
  To investigate the susceptibility of cervical carcinoma cells (HPV16+) to CTL lysis affected by rSIFN-co, consensus Interferon (Infergen), IFNalpha-2b and DDP.
  
  
  METHODS
  After CaSki cervical cancer cells were induced by rSIFN-co, Infergen, IFNalpha-2b and DDP at the concentration of 0.156 microg/mL, 0.625 microg/mL, 2.500 microg/mL for 72 hours, CaSki cells which had been induced were effected by CTL, the cytotoxicity was determined and calculated by MTT assay. The expression intensity of adhesion molecules on Caski cell such as CD54 and CD40 was also determined by flow cytometry.
  
  
  RESULTS
  The susceptibility of CaSki cell to CTL lysis under the stimulation of rSIFN-co was better than Infergen, IFNalpha-2b and DDP induced. The expression of CD54 and CD40 on cervical cancer cell was also increased. And this effect had positive correlation to the drug concentration.
  
  
  CONCLUSIONS
  rSIFN-co can increase the expression of CD54 and CD40 on the cervical cancer cell surface, and increase the susceptibility of CaSki cell to specific effective cell lysis in a dose-dependent manner. The effect of rSIFN-co is better than same type interferon, general I type interferon and chemotherapeutic drug induced.
authors.affiliation: Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Chen
authors.forename: Yue-dong
authors.initials: YD
authors.lastname: He
authors.forename: Xiao-ling
authors.initials: XL
authors.lastname: Pan
authors.forename: Xia
authors.initials: X
authors.lastname: Liu
authors.forename: Zeng-zhen
authors.initials: ZZ
authors.lastname: Lai
mesh_terms: D019013:CD40 Antigens / Q000378:metabolism; D003602:Cytotoxicity, Immunologic / Q000276:immunology*; D005260:Female; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D007371:Interferon-gamma / Q000494:pharmacology*; D011994:Recombinant Proteins; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014407:Tumor Cells, Cultured; D002583:Uterine Cervical Neoplasms / Q000276:immunology* / Q000473:pathology*
chemical_list: D019013:CD40 Antigens; D011994:Recombinant Proteins; D018799:Intercellular Adhesion Molecule-1; D007371:Interferon-gamma